Cynvenio is proud to work in partnership with leading cancer experts and organizations throughout the world. Read what they’re saying about us.


As an oncologist for 20 years, I believe what has been sold as “personalized medicine” to physicians and their patients is woefully inadequate. That’s why I am proud of the comprehensive approach taken at Cynvenio.

– Dr. Paul Y. Song, Chief Medical Officer, Cynvenio Biosystems, Inc.


The ability to intervene and to monitor the effect of your intervention without being so invasive has enormous potential. This could be applicable to a variety of tumor types and clinical stages of disease.

– Dr. Simon Tchekmedyian, Director of Oncology, St. Mary Medical Center


Blood-based molecular tests, collectively known as liquid biopsies, have the tremendous potential to advance our understanding of solid tumor biology by allowing detection of genomic abnormalities, real-time longitudinal monitoring and identification of treatment resistance. The early detection of disease at the molecular level can bring the possibility of cure within reach.

– Dr. Massimo Cristofanilli, Associate Director for Precision Medicine & Translational Research,
Robert H. Lurie Comprehensive Cancer Center Northwestern University


ClearID® is another tool in our toolbox that allows us to screen patients for early recurrence, or for a change in their disease status.

– Dr. Lee S. Schwartzberg, Senior Partner and Medical Director, The West Clinic

/*This is to open gallery links in new window*/